FiercePharma11d
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...
FiercePharma5d
ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide
Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...
pharmaphorum4d
ESMO: Incyte's PD-1 treads new ground in anal cancer
Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...
Business Wire7d
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and ...
F. Hoffmann-La Roche Ltd: FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq1,2New subcutaneous (SC) op ...
MedPage Today5d
Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer
PFS was 9.3 months for patients treated with the anti-PD-1 monoclonal antibody versus 7.4 months for ... largest known phase III trial of a checkpoint inhibitor in squamous cell anal cancer -- a ...
EurekAlert!24d
Research spotlight: Key regulators of pd-1 in melanoma cells and the immune system’s response
Immune checkpoint inhibitors are cancer fighting drugs that help the immune system do its job of detecting and attacking tumor cells. Programmed Cell Death 1 (PD-1) is a common target for this ...
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2…
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...
Yahoo Finance27d
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
The current labeling for approved checkpoint inhibitors in this indication reflects broad approvals in the intent to treat patient populations agnostic of programmed death cell ligand-1 (PD-L1 ...